Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company committed to discovering, developing, and deploying psychedelic-inspired medicines and therapies to treat brain health disorders, with a significant focus on conditions like Generalized Anxiety Disorder (GAD) and ADHD. The company leverages a technology-enabled approach, including the application of Artificial Intelligence (AI) and machine learning in areas such as drug discovery, clinical trial optimization, and the development of digital therapeutics. MindMed's pipeline includes innovative treatments derived from psychedelic substances like LSD and MDMA, aiming to provide new hope for patients with unmet medical needs.
Serves as the primary hub for corporate strategy, investor relations, U.S. clinical development oversight, and financial operations.
Situated in the iconic One World Trade Center, a globally recognized landmark known for its modern architecture and state-of-the-art facilities.
Dynamic, innovative, and mission-driven, characteristic of a pioneering biotech firm. The culture likely emphasizes scientific rigor, collaboration, and the integration of cutting-edge technologies like AI in its research and development processes.
The New York City location provides strategic access to global financial markets, leading research institutions, and a diverse talent pool. The prestige of One World Trade Center underscores the company's ambitious vision.
MindMed operates with a global outlook, conducting clinical trials in North America and Europe. Its international presence supports worldwide research collaborations, engagement with regulatory authorities like the FDA and EMA, and strategic partnerships. The company utilizes global talent and resources, including AI and data science expertise, to advance its pipeline of psychedelic-inspired medicines and digital health technologies for brain disorders.
One World Trade Center, Suite 8500
New York
NY
USA
Address: Viaduktstrasse 8, 4051 Basel, Switzerland
Leverages Switzerland's robust pharmaceutical ecosystem, access to European regulatory bodies, research talent, and facilitates collaboration with international partners.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Mind Medicine (MindMed) Inc.' leadership includes:
Mind Medicine (MindMed) Inc. has been backed by several prominent investors over the years, including:
Over the past 12 months, Mind Medicine (MindMed) Inc. has made strategic appointments to its executive team, including a new Chief Commercial Officer and a new General Counsel, to support its growth and development pipeline. These changes reflect the company's ongoing efforts to strengthen its leadership as it advances its clinical programs.
Discover the tools Mind Medicine (MindMed) Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Mind Medicine (MindMed) Inc. commonly uses the email format [first].[last]@mindmed.co for its professional communications. This format is widely adopted within the organization.
[first].[last]@mindmed.co
Format
robert.barrow@mindmed.co
Example
90%
Success rate
MindMed Press Release / Business Wire • May 9, 2024
MindMed announced its Q1 2024 financial results, detailing progress in its MM-120 program for GAD, including continued analysis of Phase 2b data and preparations for its End-of-Phase 2 meeting with the FDA. The company emphasized its focus on advancing its pipeline and maintaining a strong financial position....more
MindMed Press Release / Business Wire • March 7, 2024
MindMed shared positive 12-week durability data from its Phase 2b trial of MM-120 (lysergide d-tartrate) for Generalized Anxiety Disorder (GAD), showing sustained and clinically meaningful improvements in symptoms, supporting its potential as a long-acting treatment....more
MindMed Press Release / Business Wire • December 14, 2023
MindMed announced a research collaboration with the Lieber Institute for Brain Development (LIBD) to analyze LIBD’s extensive genomic and phenotypic data. This partnership aims to identify and validate novel drug targets, potentially utilizing AI and computational biology, to accelerate the development of treatments for neuropsychiatric disorders....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Mind Medicine (MindMed) Inc., are just a search away.